skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination

Review

(1544) Views  (466) Full article downloads

Authors: Konstantinos Savvatis, Dirk Westermann, Heinz-Peter Schultheiss, et al

Published Date December 2010 Volume 2010:3 Pages 163 - 170
DOI: http://dx.doi.org/10.2147/IBPC.S13448

Konstantinos Savvatis1, Dirk Westermann1, Heinz-Peter Schultheiss1, Carsten Tschöpe1,2
1Charité Universitätsmedizin Berlin, Department of Cardiology and Pneumonology, Campus Benjamin Franklin, Berlin; 2Charité Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Campus Virchow-Klinikum, Berlin, Germany

Abstract: Arterial hypertension is one of the major diseases in the Western world. It is an independent cardiovascular risk factor and is associated with increased morbidity and mortality. Several drug classes have been shown to be effective in the treatment of hypertension. Aliskiren is a direct renin inhibitor and belongs to the class of renin-angiotensin-aldosterone system inhibitors. Several large studies have shown that aliskiren is effective in lowering blood pressure, and equivalent in this respect to the angiotensin-converting enzyme (ACE) inhibitors and the angiotensin receptor-1 blockers (ARBs). Furthermore, aliskiren has a safety and tolerability profile comparable with that of the ARBs and slightly better than that of the ACE inhibitors. From a pathophysiologic perspective, it can be combined with hydrochlorothiazide successfully, because it can block the diuretic-induced increase in plasma renin activity. Its combination with hydrochlorothiazide in a single pill has been investigated and shown to be superior to monotherapy with respect to blood pressure control and improvement in patient compliance with therapy. Further studies are needed to show whether aliskiren and its combination with hydrochlorothiazide is effective in preventing cardiovascular events and mortality when end organ damage is present.

Keywords: aliskiren, hydrochlorothiazide, combination, hypertension






Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Cuff inflation during ambulatory blood pressure monitoring and heart rate
Hematocrit and mean arterial blood pressure in pre- and postmenopause women
Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials
Differences between the combination of the 25-gauge vitrectomy with phacoemulsification versus 20-gauge vitrectomy and phacofragmentation
Evidence-based approach for managing hypertension in type 2 diabetes
Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
Optimal management of hypertension in elderly patients
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University